VALION BIO INC (VBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.77-1.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -45.4% |
| Our one-year growth estimate | diamond | -49.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 4.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
VBIO — CEO transition
Dated 2026-08-17
CEO — Michael K. Handley: The CEO was terminated effective immediately, which constitutes a sudden executive departure rather than a routine succession or promotion.
Why it matters: Worsening cash burn could signal deeper financial issues. This affects the company's financial health.
Worry ifCash from operating activities worsens from -$5.28M in 2026-Q2.
Less concerning ifCash from operating activities improves or stays the same in 2026-Q3.
Why it matters: Higher operating expenses show financial health is getting worse. This can lead to more cash burn and worry from investors.
Worry ifOperating expenses go beyond -$5.63 million in Q2.
Less concerning ifOperating expenses stay the same or improve, below -$5.63 million in Q2.
Why it matters: Expanding facilities is important for growth. Doing this well can increase production.
Supportive ifThe new facility lease is for 8,024 square feet. It is ready to operate.
Worry ifDelays or canceling the expansion plans are bad signs.
Why it matters: Controlling expenses is key to managing cash burn. It affects financial health and investor trust.
Supportive ifOperating expenses drop in 2026-Q3 compared to 2026-Q2.
Worry ifOperating expenses increase or stay the same in 2026-Q3.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$392 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $1,393 loss on $10,000 · 13.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,648 loss on $10,000 · 96.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The reverse stock split aims to help Valion regain Nasdaq compliance. A successful outcome is crucial for its listing.
Supportive ifThe stock price trades above $1.00 for at least 10 consecutive trading days after the split.
Worry ifThe stock price remains below $1.00 for 30 consecutive trading days after the split.
Why it matters: Advancing Entolimod is key to Valion's growth strategy. Progress can attract partnerships and funding.
Supportive ifA press release says Entolimod's clinical trials hit a key milestone.
Worry ifThere is a delay or problem with Entolimod's clinical trials or approvals.
Why it matters: Managing net losses is crucial for financial stability. Staying within the guided range shows effective cost control.
Supportive ifNet loss reported between $8.8M and $9.1M for 2025.
Worry ifNet loss exceeds $9.1M for 2025.